General Information of the Compound
Compound ID
CP0479432
Compound Name
5-[5-oxo-8-[6-(4-piperidyloxy)- 3-pyridyl]-7-thioxo-6,8- diazaspiro[3.4]octan-6-yl]-3- (trifluoromethyl)pyridine-2- carbonitrile
    Show/Hide
Synonyms
2110426-27-0
5-(8-oxo-5-(6-(piperidin-4-yloxy)pyridin-3-yl)-6-thioxo-5,7-diazaspiro[3.4]octan-7-yl)-3-(trifluoromethyl)picolinonitrile
EX-A1808
OUEHJEYKNYQVRC-UHFFFAOYSA-N
SCHEMBL19128768
TRC-253
TRC253
    Show/Hide
Structure
Formula
C23H21F3N6O2S
Molecular Weight
502.522
Canonical SMILES
FC(F)(F)c1cc(cnc1C#N)N1C(=S)N(c2ccc(OC3CCNCC3)nc2)C2(CCC2)C1=O
    Show/Hide
InChI
InChI=1S/C23H21F3N6O2S/c24-23(25,26)17-10-15(13-29-18(17)11-27)31-20(33)22(6-1-7-22)32(21(31)35)14-2-3-19(30-12-14)34-16-4-8-28-9-5-16/h2-3,10,12-13,16,28H,1,4-9H2
    Show/Hide
InChIKey
OUEHJEYKNYQVRC-UHFFFAOYSA-N
CAS
2110426-27-0
Physicochemical Property
logP
3.55868
Rotatable Bonds
4
Heavy Atom Count
35
Polar Areas
94.38
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
7
Complexity
35

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 130229812
ChEMBL ID
CHEMBL4858811
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00894, Androgen receptor
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000141 LNCaP Homo sapiens (Human)  2
1
IC50 = 37 nM
   TI
   LI
   LO
   TS
2
IC50 = 54 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( TRC-253 )
Drug Name TRC-253
Company Janssen Research & Development Raritan, NJTRACON PharmaceuticalsSan Diego, CA
Indication
Prostate cancer
Phase 1/2
Target(s)
Androgen receptor messenger RNA (AR mRNA)
Antagonist